Table 2. Clinicopathologic characteristics in patients with progression.

		Progressive Disease (PD)
		No (n=26)	Yes (n=6)	P-value
Age, median (range)		52 (21-76)	59 (52-71)	0.049+
Sex	Male	18(90%)	2(10%)	0.17
	Female	8(66.7%)	4(33.3%)	.
Race	White	24(82.8%)	5(17.2%)	0.48
	Black	0(0%)	1(100%)	.
	Hispanic	1(100%)	0(0%)	.
	Asian	1(100%)	0(0%)	.
Smoking Status	Never Smoker	12(92.3%)	1(7.7%)	0.17
	Former smoker	8(88.9%)	1(11.1%)	.
	Current smoker	6(60%)	4(40%)	.
Differentiation	Well	1(100%)	0(0%)	0.70
	Mod	7(87.5%)	1(12.5%)	.
	Poorly	11(84.6%)	2(15.4%)	.
	Moderately well	1(50%)	1(50%)	.
	Poorly-Moderately	2(100%)	0(0%)	.
T Stage	T1-T2	18(86%)	3(14%)	0.003
	T3-T4	8(73%)	3(27%)	.
N Stage	N2B	19(90.5%)	2(9.5%)	0.090
	N2C	5(62.5%)	3(37.5%)	.
	N3	1(50%)	1(50%)	.
EGFR++	0	0 (0%)	0 (0%)	0.78
	1+	4(100%)	0(0%)
	2+	5(100%)	0(0%)
	3+	37(82.2%)	8(17.8%)
HPV+++	HPV-positive	12 (100%)	0(0%)	0.008
	HPV-negative	8 (57%)	6(43%)

⁺p-value from Wilcoxon Rank sum test, all other p-values from the Fisher’s exact test

⁺⁺Available for 24 patients

⁺⁺⁺Available for 26 patients